Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539555 | 0.88 | KDM4E (0.41) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL20365655 | 0.88 | AKT1 (0.40) | — | |
| SCHEMBL18528170 | 0.83 | KDM4E (0.47) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL18528179 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL18551903 | 0.77 | ALOX15 (0.35) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL18528208 | 0.75 | AURKA (0.46) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL20365697 | 0.75 | AURKA (0.46) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL18528189 | 0.74 | AURKA (0.46) | KDM4EAURKAALDH1A1KMT2AMEN1 | |
| SCHEMBL28910711 | 0.72 | KDM4E (0.43) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL18539558 | 0.70 | KDM4E (0.48) | KDM4EAURKAALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345909-B1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-3345909-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9670219-B2 | Tetrahydrooxepinopyridine compound | ASTELLAS PHARMA INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670219-B2 | Tetrahydrooxepinopyridine compound | ASTELLAS PHARMA INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9670219-B2 | Tetrahydrooxepinopyridine compound | ASTELLAS PHARMA INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-02-23 | — | — | US | disclosed |
| WO-2017030171-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | アステラス製薬株式会社 | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050973-A1 | TETRAHYDROOXEPINOPYRIDINE COMPOUND | CHRNA7, CHRNA5, P2RX7 | KDM4E 2924/4885AURKA 3801/4885ALDH1A1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.